secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cigna Group (CI)
CIK:        0001739940
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950159-24-000103
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cigna raises long-term adjusted EPS growth target to 10%-14%; reaffirms FY2024 guidance of at least $28.25
--------------------------------------------------------------------------------

- Long-term average annual adjusted EPS growth target raised to 10%-14% from prior target.
- 2024 adjusted EPS guidance reaffirmed at least $28.25 per share.
- Launches EncircleRx: industry-first financial guarantee for GLP-1s to help cap employer costs.
- Evernorth Behavioral Care Group launched; guarantees appointment within 72 hours, scales by 2025.
- Evernorth plans Humira biosimilar at $0 out-of-pocket for eligible Accredo patients by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739940/000095015924000103/0000950159-24-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739940/000095015924000103/cigna8k.htm
  HTML page:      https://secwatch.observer/filing/0000950159-24-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer